Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06577636 · ClinicalTrials.gov registry record · Phase 2
Induction of Dreaming With EEG and Anesthesia for Post-traumatic Stress Disorder
A Phase 2 study of Post Traumatic Stress Disorder and PTSD, sponsored by Stanford University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
- 1
- Study location
NCT06577636: Recruiting Phase 2 study of Post Traumatic Stress Disorder and PTSD, sponsored by Stanford University.
NCT06577636 is a Phase 2 study of Post Traumatic Stress Disorder and PTSD that is actively recruiting participants, run by Stanford University. The registered enrollment target is 42 participants, below the 664-participant average among 262 other Post Traumatic Stress Disorder trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06577636, a Phase 2 study of Post Traumatic Stress Disorder and PTSD, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to test whether anesthesia-induced dreaming can help alleviate symptoms of PTSD in an (1) open-label trial (Phase I) and (2) double-blind, randomized controlled trial (Phase II) in a non-surgical setting. The investigators predict that inducing and sustaining a dream state prior to emergence from anesthesia will result in reduced symptoms of PTSD. Participants will undergo EEG-guided propofol anesthesia during which they will be either (1) receiving deep sedation leading to loss of responsiveness, designed to elicit dream reports upon emergence (Dream Protocol), and/or (2) light sedation without loss of responsiveness, designed to elicit non-dream experiential reports while responsive (e.g., simple imagery, sounds, thoughts, bodily sensations, hypnagogic-like experiences) (Non-Dream Protocol). The investigators will then investigate whether the deep-sedation Dream Condition is associated with a larger reduction in PTSD symptoms than the light-sedation Non-Dream Condition.
Primary Outcome
The CAPS-5 is a structured interview that is considered the gold standard for assessing post-traumatic stress disorder (PTSD). The CAPS-5 is designed to assess the 20 symptoms of PTSD as defined by the DSM-5, as well as the impact of these symptoms on social and occupational functioning. The CAPS-5 includes 20 items corresponding to the DSM-5 criteria for PTSD. Each item is rated for both frequency and intensity, with a 5-point scale (0-4) for each dimension. The total score ranges from 0 to 80,
Conditions Studied
Interventions
- PROCEDURE Propofol anesthesia
Study Locations (1)
California
- Stanford University - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2025-07-21 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
What NCT06577636 shows while recruiting
NCT06577636 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 664-participant average among 262 other Post Traumatic Stress Disorder trials with a reported enrollment target (94% lower).
The record links to 2 conditions, with Post Traumatic Stress Disorder appearing as the primary indexed condition, and to 1 intervention - of which Propofol anesthesia is the first listed.
NCT06577636 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06577636 about?
NCT06577636 is a clinical study titled "Induction of Dreaming With EEG and Anesthesia for Post-traumatic Stress Disorder". The goal of this study is to test whether anesthesia-induced dreaming can help alleviate symptoms of PTSD in an (1) open-label trial (Phase I) and (2) double-blind, randomized controlled trial (Phase II) in a non-surgical setting. The investigators predict that inducing and sustaining a dream state ...
What is the current status of trial NCT06577636?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2025-07-21. Estimated completion is 2026-12.
What conditions does trial NCT06577636 study?
This clinical trial studies the following conditions: Post Traumatic Stress Disorder, PTSD.
What interventions are being tested in trial NCT06577636?
The interventions under investigation include: Propofol anesthesia (PROCEDURE).
Who is sponsoring clinical trial NCT06577636?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06577636 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Post Traumatic Stress Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06577636's enrollment target sits among peer trials
42 185th of 262 higher than 78 of 262 other Post Traumatic Stress Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Post Traumatic Stress Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Department of Defense PTSD Adaptive Platform Trial - Intervention A - Fluoxetine
RECRUITING · Phase 2
-
Facilitation of Extinction Retention and Reconsolidation Blockade by IV Allopregnanolone in PTSD.
RECRUITING · Phase 2
-
Facilitation of Extinction Retention and Reconsolidation Blockade in PTSD
RECRUITING · Phase 2
-
Department of Defense PTSD Adaptive Platform Trial - Master Protocol
RECRUITING · Phase 2
-
MDMA for AUD/PTSD Comorbidity
RECRUITING · Phase 2
-
Enhancing Transdiagnostic Mechanisms of Cognitive Dyscontrol (R33)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI